论文部分内容阅读
目的探讨诺和灵和口服降糖药治疗2型糖尿病(T2DM)的临床疗效和安全性。方法将56例T2DM患者,随机分为A、B、C组,A组17例,使用诺和灵治疗;B组11例,使用诺和灵联合口服降糖药治疗;C组28例,使用口服降糖药治疗。动态跟踪患者,定期监测FPG、2PG、HBA1C等情况指标;结果 A组的疗效明显优秀于另外两组,P<0.05。结论诺和灵联合口服降糖药治疗2型糖尿病明显优于单用口服胰岛素和口服药。
Objective To investigate the clinical efficacy and safety of Novolin and oral hypoglycemic agents in the treatment of type 2 diabetes mellitus (T2DM). Methods Fifty-six patients with T2DM were randomly divided into A, B and C groups, 17 cases in group A were treated with noradrenaline, 11 cases in group B were treated with Novolin together with oral hypoglycemic agents, and 28 cases in group C Oral hypoglycemic agents. Dynamic follow-up of patients, regular monitoring of FPG, 2PG, HBA1C and other indicators; Results The efficacy of group A was significantly better than the other two groups, P <0.05. Conclusions Novolin and oral hypoglycemic agents are significantly superior to those of oral insulin and oral drugs alone in the treatment of type 2 diabetes mellitus.